Nicox

NicOx is a French pharmaceutical company seeking to become an ophthalmology specialist. Its core nitric oxide-donating platform creates new versions of existing drugs. BOL-303259-X is entering Phase III trials for glaucoma in partnership with Bausch+Lomb.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: Europe’s ageing buildings

Stock of the month – PZ Cussons

Q226 reflections: Leadership swings back – the value case holds

Audiovisual

Latest

The Metals Company – equity proposition

Vantage: Rockwood Strategic – UK small-cap value and active engagement

Bull, Bear & Beyond – Living REIT: executive interview

About Edison

Corporates

Investors

Careers

Nicox (Euronext Growth: ALCOX)

Latest Insights

Nicox — Animal data show favourable profile vs Lumigan

Nicox — Q323 update confirms trajectory for NCX-470

Nicox — Denali trial remains on track for 2025 readout

Nicox — Nicox provides NCX-470 sales potential estimates

Market Data

Sector

Research

Nicox — €10m financing boosts cash runway into Q224

Nicox — Revising NCX-470 forecasts after Mont Blanc

Nicox — Q4 highlights confirm continued Vyzulta growth

Nicox — NCX-470 non-inferior to latanoprost in Mont Blanc

Nicox — Looking ahead to Mont Blanc study readout

Nicox — Revising NCX-470 timelines given Denali delay

Nicox — Moving towards key Mont Blanc data in Q4

Nicox — Mont Blanc top-line data timelines pushed forward

Nicox — Eye health portfolio targets large markets

Nicox — New governance structure

Nicox – executive interview

Nicox — Funded through key milestones

Nicox — Mississippi data shows benefit in dry eye

Nicox — Commercial products continue to grow

Nicox — NCX-4251 setback sharpens focus on NCX-470

Nicox — Continuing to move towards data inflection points

Nicox — Key programmes continue to advance

Nicox — No surprises as NCX-470 Phase III trials advance

Nicox – Edison Open House interview

Nicox — Focus on sight

Edison explains: Investing in health stocks – how policy clarity is opening doors

The CNS renaissance: Innovations are reshaping neurological therapies

Healthcare-focused trusts: A sector on the mend

Outlook for 2024: Life sciences – where has the conviction gone?

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide